Comparative Pharmacology
Head-to-head clinical analysis: HI COR versus TRIANEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HI COR versus TRIANEX.
HI-COR vs TRIANEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
Triamcinolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
0.1-0.2 mg/kg intravenously once.
50 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites.
Category C
Category C
Corticosteroid
Corticosteroid